Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii

  1. Irini Pateraki  Is a corresponding author
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
  1. University of Copenhagen, Denmark
  2. University of California, Berkeley, United States
  3. Evolva, Denmark
  4. Nofima, Norway
  5. KTH - Royal Institute of Technology, Sweden
  6. Michigan State University, United States

Abstract

Forskolin is a unique structurally complex labdane type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.

Article and author information

Author details

  1. Irini Pateraki

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    eipa@plen.ku.dk
    Competing interests
    Irini Pateraki, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7526-2334
  2. Johan Andersen-Ranberg

    Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Johan Andersen-Ranberg, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  3. Niels Bjerg Jensen

    Evolva, Copenhagen, Denmark
    Competing interests
    Niels Bjerg Jensen, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compoundsEmployee of Evolva SA.
  4. Sileshi Gizachew Wubshet

    Nofima, Osloveien, Norway
    Competing interests
    No competing interests declared.
  5. Allison Maree Heskes

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-5185
  6. Victor Forman

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  7. Björn Hallström

    Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  8. Britta Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    No competing interests declared.
  9. Mohammed Saddik Motawia

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  10. Carl Erik Olsen

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  11. Dan Staerk

    Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  12. Jørgen Hansen

    Evolva, Copenhagen, Denmark
    Competing interests
    Jørgen Hansen, Employee of Evolva SA.
  13. Birger Lindberg Møller

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    Birger Lindberg Møller, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  14. Bjoern Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    Bjoern Hamberger, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds'.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1249-1807

Funding

Villum Fonden

  • Birger Lindberg Møller

Novo Nordisk

  • Birger Lindberg Møller

European Commission

  • Irini Pateraki

DOE Office of Science (BER DE-FC02-07ER64494)

  • Bjoern Hamberger

Strategic Partnership Grant (15-SPG-Full-3101)

  • Bjoern Hamberger

MSU Foundation

  • Bjoern Hamberger

Michigan State University (startup funding from the Department of Molecular Biology and Biochemistry)

  • Bjoern Hamberger

Michigan State University (AgBioResearch - MICL02454)

  • Bjoern Hamberger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Pateraki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,142
    views
  • 821
    downloads
  • 99
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Irini Pateraki
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
(2017)
Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii
eLife 6:e23001.
https://doi.org/10.7554/eLife.23001

Share this article

https://doi.org/10.7554/eLife.23001

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.

    1. Biochemistry and Chemical Biology
    Yingjie Sun, Changheng Li ... Youngnam N Jin
    Research Article

    Identifying target proteins for bioactive molecules is essential for understanding their mechanisms, developing improved derivatives, and minimizing off-target effects. Despite advances in target identification (target-ID) technologies, significant challenges remain, impeding drug development. Most target-ID methods use cell lysates, but maintaining an intact cellular context is vital for capturing specific drug–protein interactions, such as those with transient protein complexes and membrane-associated proteins. To address these limitations, we developed POST-IT (Pup-On-target for Small molecule Target Identification Technology), a non-diffusive proximity tagging system for live cells, orthogonal to the eukaryotic system. POST-IT utilizes an engineered fusion of proteasomal accessory factor A and HaloTag to transfer Pup to proximal proteins upon directly binding to the small molecule. After significant optimization to eliminate self-pupylation and polypupylation, minimize depupylation, and optimize chemical linkers, POST-IT successfully identified known targets and discovered a new binder, SEPHS2, for dasatinib, and VPS37C as a new target for hydroxychloroquine, enhancing our understanding these drugs’ mechanisms of action. Furthermore, we demonstrated the application of POST-IT in live zebrafish embryos, highlighting its potential for broad biological research and drug development.